Global Point-of-Care Diagnostics Market Size By Type (Glucose Monitoring Kits, Infectious Diseases Testing Kits), By Application (Home, Hospitals), By Region, And Segment Forecasts, 2023 to 2032

lobal Point-of-Care Diagnostics Market Report Description

The Global Point-of-Care (POC) Diagnostics Market was valued at USD 45.3 billion in 2023 and is projected to surpass USD 87.6 billion by 2031, growing at a CAGR of 8.6% during the forecast period (2023–2031). The rapid growth is fueled by increasing demand for decentralized healthcare solutions, the rising prevalence of chronic and infectious diseases, and technological advancements in diagnostic platforms.

Point-of-care diagnostics allow healthcare providers to obtain rapid, accurate test results at or near the site of patient care, reducing turnaround time and improving clinical decision-making. The COVID-19 pandemic further accelerated the adoption of POC testing, highlighting its critical role in emergency and primary care settings.

Drivers

Growing Prevalence of Chronic & Infectious Diseases

Rising cases of diabetes, cardiovascular diseases, HIV, and respiratory infections have significantly increased the demand for quick and reliable diagnostic tests that can be conducted outside central laboratories.

Technological Advancements

Innovations such as miniaturized devices, integration of AI-driven analytics, and the development of multiplexed platforms have enhanced the accuracy and usability of POC diagnostic solutions.

Increasing Adoption of Decentralized Healthcare

The shift towards patient-centric care, especially in rural and resource-limited areas, is driving the adoption of portable, easy-to-use POC diagnostic kits that support home care and remote monitoring.

Restraints

Regulatory and Quality Concerns

Stringent regulatory approvals and the need for compliance with quality standards can delay product launches and market expansion.

Limited Reimbursement Policies

Inadequate reimbursement frameworks in several countries hinder widespread adoption of POC diagnostic tests, especially in emerging markets.

Opportunity

Integration with Digital Health & Telemedicine

The combination of POC diagnostics with telehealth platforms creates opportunities for remote patient monitoring and improved disease management.

Expansion in Emerging Markets

Countries in Asia-Pacific, Latin America, and Africa present significant growth potential due to increasing healthcare investments and the need for affordable, rapid diagnostics.

Development of Next-Generation Biosensors

Advancements in biosensors, microfluidics, and molecular diagnostics offer opportunities for more sophisticated, cost-effective, and accessible POC solutions.

Market by System Type Insights

Lateral Flow Assays (LFAs) dominated the market in 2023 due to their cost-effectiveness and ease of use, particularly for infectious disease testing.

Molecular Diagnostics-based POC tests are expected to experience the highest growth, driven by the demand for highly sensitive and specific tests for critical conditions such as sepsis, cancer, and respiratory infections.

Market by End-use Insights

Hospitals & Clinics accounted for the largest share in 2023 due to the growing need for rapid diagnostics in emergency and outpatient settings.

Home Healthcare Settings are expected to witness the fastest growth, supported by the rise in self-testing kits for chronic disease monitoring, pregnancy testing, and infectious disease screening.

Market by Regional Insights

North America led the global market in 2023, driven by strong healthcare infrastructure, high adoption of advanced diagnostic technologies, and favorable regulatory frameworks.

Asia-Pacific is projected to register the highest growth rate during the forecast period, owing to expanding healthcare access, rising disease burden, and government initiatives to promote decentralized healthcare.

Europe maintains a substantial share, fueled by increased investments in point-of-care solutions for elderly care and infectious disease management.

Competitive Scenario

Key players in the Global Point-of-Care Diagnostics Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, BD (Becton, Dickinson and Company), bioMérieux, QuidelOrtho, Nova Biomedical, Cepheid (Danaher), and EKF Diagnostics.

2023: Abbott launched its next-generation molecular POC platform for rapid COVID-19 and respiratory virus detection.

2024: Roche Diagnostics expanded its POC testing portfolio by integrating AI-driven decision support for cardiovascular and infectious disease diagnostics.

2025: Siemens Healthineers partnered with leading telemedicine providers to integrate POC diagnostics with digital health platforms for remote patient care.

Scope of Work – Global Point-of-Care Diagnostics Market

Key Market Developments

2023: Abbott Laboratories launched a portable multiplexed POC platform for respiratory and gastrointestinal infections.

2024: Roche Diagnostics introduced AI-enabled interpretation software for improved accuracy of rapid POC tests.

2025: Siemens Healthineers developed an integrated home-care POC device with smartphone connectivity for chronic disease monitoring.

FAQs

1. What is the current market size of the Global Point-of-Care Diagnostics Market?

The market was valued at USD 45.3 billion in 2023.

2. What is the major growth driver of the Global Point-of-Care Diagnostics Market?

The major driver is the increasing prevalence of chronic and infectious diseases along with the demand for rapid, decentralized diagnostics.

3. Which is the largest region during the forecast period in the Global Point-of-Care Diagnostics Market?

North America is expected to remain the largest region due to its advanced healthcare infrastructure and early adoption of POC technologies.

4. Which segment accounted for the largest market share in the Global Point-of-Care Diagnostics Market?

The Lateral Flow Assays (LFAs) segment held the largest share in 2023.

5. Who are the key market players in the Global Point-of-Care Diagnostics Market?

Major players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, and BD.

Would you like me to generate a downloadable DOCX report in the same professional format for your use?